Since in the literature, the frequency of TP53 loss of function in RS is indicated as ~50% of RS cases (18, 19), the incongruence between our model and the RNA data highlights the need to consider tumor heterogeneity when investigating molecular mechanisms of the disease. This evidence concerns the gene TP53 and neoplasm.